Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 4;10(1):141. doi: 10.3390/jcm10010141

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Flow chart of included patients. PR-TAC, prolonged-release tacrolimus; MMF, mycophenolate mofetil; P, prednisone; LCP-TAC, extended-release tacrolimus; IR-TAC, immediate-release tacrolimus; i-mTOR, inhibitors of mammalian target of rapamycin. Contraindications for the first surveillance biopsy include treatment with oral anticoagulants (n = 33), large abdominal obesity (n = 26), technical difficulties due to perirenal hematoma or lymphocele (n = 9), idiomatic barrier (n = 13), and horseshoe kidneys (n = 4). Indications for the use of mTOR inhibitors in this cohort was as follows: inclusion in a clinical trial containing i-mTOR de novo or early conversion (n = 16), polyoma BK viremia during follow up (n = 6), CMV viremia after prophylaxis in high-risk recipients (n = 8) and skin cancer (n = 2). High immunological risk patients were defined as those with HLA donor-specific antibodies at the time of transplant (n = 7) or receiving a desensitization treatment before transplant (n = 5).